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Abstract Tyrosine phosphorylation of the nicotinic ace- 
tylcholine receptor (AChR) may be involved in AChR desensitiza- 
tion and clustering. Torpedo AChR y-subunit is phosphorylated 
at Tyr365. Using overlapping synthetic peptides, we have precisely 
mapped the epitopes of five anti-y-subunit monoclonal antibodies 
(mAbs) and found that the epitope(s) for the mAhs 154,165 and 
168 (~365-370) all contain Tyrx5. mAb 168 is a known blocker 
of AChR channel function. Using peptide analogues, TyrM5 was 
found to be indispensable for mAb16S binding; furthermore its 
binding was selectively inhibited by in vitro AChR tyrosine phos- 
phorylation. The possible connection between y-subunit phospho- 
rylation and regulation of AChR function and the proven useful- 
ness of these mAbs as tools should facilitate functional studies of 
AChR y-subunit phosphorylation. 
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1. Introduction 
The nicotinic acetylcholine receptor (AChR) from fish elec- 
tric organs is a transmembrane glycoprotein composed of five 
homologous subunits in the stoichiometry@By6. Acetylcholine 
binds to the two a-subunits and regulates the opening of the 
AChR ion channel. The channel is formed from all five sub- 
units, which are arranged in a pentameric rosette (reviewed in 
[la. 
The AChR is phosphorylated by CAMP-dependent protein 
kinase, protein kinase C and at least two endogenous protein 
tyrosine kinases [3,4]. The protein tyrosine kinases phospho- 
rylate the /?, y and 6 subunits at flyr355, yTyr365 and Sryr372 
[5]. AChR tyrosine phosphorylation seems to be involved in 
AChR clustering and in increasing its desensitization rate [6-81. 
The availability of specific tools should be invaluable in study- 
ing the individual role of each single phosphorylation site. 
Monoclonal antibodies (mAbs) against specific sites on the 
AChR offer such a set of powerful probes for studying AChR 
phosphorylation. Eleven anti+subunit mAbs bind to a very 
immunogenic cytoplasmic epitope @352-359) containing the p- 
subunit phosphorylation site (/3Tyr355) [9]. One of these mAbs 
(No. 148) is known to block the AChR channel [lO,l l] and its 
binding is partially inhibited by AChR tyrosine phosphoryla- 
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dodecyl sulphate; SDS-PAGE, SDS-polyacrylamide gel electro- 
phoresis. 
tion [9]. The epitope for one anti-&subunit mAb contains 
JTyr372 and that for another contains the serine phosphoryla- 
tion site 6Ser3” [ 121. The epitopes for our anti-y-subunitmAbs 
were previously mapped at a relatively low resolution [13] 
which did not permit the accurate localization of the epitopes 
involved and their relationship to the phosphorylation sites. 
In this paper, the fine epitope mapping of five mAbs on the 
Torpedo AChR y-subunit revealed an interesting association 
between y-subunit phosphorylation and regulation of AChR 
function; it also demonstrated that these mAbs should prove 
to be highly specific tools in subsequent studies on the role of 
AChR y-subunit tyrosine phosphorylation. 
2. Materials and methods 
2.1. Peptide synthesis 
Peptides were synthesized on the tips of small polyethylene rods 
coated with polymers of acrylic acid formed by radiation grafting 
[9,12,1416]. For each sequence, at least 2-3 copies (i.e. 2-3 identical 
rods) were synthesized. 
2.2. Monoclonal antibodies 
mAbs were derived from rats immunized with sodium dodecyl sulfate 
(SDS)-denatured Torpedo AChR or purified y-subunit [17,18]. The 
preparations used were 50% ammonium sulfate precipitates from hy- 
bridoma supernatants; the solubilized precipitates were dialyzed 
against 145 mM NaCl, 7.5 mM Na*HPO,, 2.5 mM NaH,PO,, pH 7.4 
(PBS), containing 0.05% NaN,. 
2.3. ELISA assays 
Enzyme-linked immunosorbent assays (ELISA) were performed as 
previously described [9]. In brief, each peptide-bearing rod was preincu- 
bated for 1 h at room temperature with 200 ~1 of PBS, containing 0.1% 
Tween-20, 0.8% bovine serum albumin and 0.2% ovalbumin, followed 
by overnight incubation at 4°C with 200 ~1 of a dilution of test mAb 
(11200 to l/5,000) in the above solution. They were washed with PBS 
containing 0.05% Tween-20, then incubated with peroxidase-labelled 
rabbit anti-rat y-globulin (DACO) for 1 h at room temperature and 
washed again. Bound mAbs were detected by reaction for 10 min with 
0.05% azino-di-3-ethylbenzthiazodinsulphonate and 0.03% H,Oz in 0.1 
M Na,HP0,/0.08 M citric acid buffer, pH 4, followed by measurement 
of the optical density of the solution at 405 nm. 
2.4. AChR preparation, tyrosine phosphorylation and mAb binding 
AChR-rich membranes were prepared from frozen Torpedo califor- 
nica electric organs (Marinus, Long Beach, Ca) and treated as described 
[9]. 32P-tyrosine phosphorylated AChR was prepared using the method 
of Wagner et al. [5] with slight modifications [9]. Extracts containing 
14 pmol “P-1abelled AChR were incubated with 0.5-2 pmol test mAb 
immobilized on CNBr activated Sepharose beads (Pharmacia) for 2 h 
at 4°C in 50 ,~l PBS containing 0.5% Triton X-100, 0.05% NaN,. [9]. 
The radioactive Sepharose beads were washed and the labelled AChR 
subunits eluted with SDS-mercaptoethanol sample buffer and subjected 
to SDS-polyacrylamide gel electrophoresis (SDS-PAGE, 10% w/v poly- 
acrylamide) [19] without boiling. After electrophoresis, the gels were 
fixed,dried and subjected to autoradiography. SDS-PAGE gels were 
occasionally subjected to alkaline treatment [20] which confirmed that 
phosphorylation involved mainly tyrosines. 
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3. Results 
3.1. Monoclonal antibody binding to overlapping y-subunit 
undecapeptides 
Fifteen undecapeptides, overlapping by eight residues and 
covering the region y35&408, were initially synthesized. The 
anti-a mAb 6, used as a negative control, did not bind to any 
peptide (not shown). mAbs 154, 165 and 168 bound mainly to 
~362-372 and ~365~375, suggesting that the critical binding 
segment lay within the common segment ~365-372. These re- 
sults also suggested that mAb 7 should bind to ~380-387 and 
mAb 145 to ~392-399 (Fig. 1A). 
Subsequently, to further localize the critical binding seg- 
ments, we synthesized overlapping peptides differing by only 
one residue and tested them for their ability to bind the corre- 
sponding mAbs. Fig. 1B suggests, but does not prove, that the 
critical binding segment for mAb 168 is ILKKP (~366-370) and 
that for mAbs 154 and 165 is YILKKP (~365~370). 
On the basis of the above results, we then synthesized se- 
lected peptides of various lengths to delineate the correspond- 
ing epitopes. Fig. 2 shows that the binding of mAbs 154, 165 
and 168 required peptides (E)YILKKP (y36&370), YILKK(P) 
(~365~370) and (Y)ILKK(PRS) (~365~372), respectively, i.e. 
sequences which are similar, but not identical, to those previ- 
ously implicated. Residues in parenthesis denote a partial con- 
tribution to mAb binding. mAb 7 needed the hexapeptide 
RHGLKR (~382-387) for efficient binding, but showed signifi- 
cant binding even to the tetrapeptide RHGL. mAb 145 required 
the hexapeptide TSDIDI (~392-397). Fig. 3 summarises the 
epitope mapping results. 
0 ^^ 
Synthetic 11-peptides 
Fig. 1. Epitope analysis of 5 anti-y-subunit mAbs. Antibodies were 
tested forbinding to undecapeptides, overlapping by eight (A) or ten (B) 
residues, derived from the Torpedo AChR y-subunit sequence 356408. 
Peptides were attached to polyethylene rods and tested for mAb binding 
by ELISA using peroxidase-labelled anti-rat y-globulin antibody. 
Synthetic peptides 
Fig. 2. Binding pattern of mAbs to selected peptides of various sizes. 
Both the peptide sequences and the corresponding positions of their 
N-terminal ends on the y-subunit are shown. Experimental conditions 
as in Fig. 1. 
3.2. Binding role of single residues within the phosphorylation 
site-containing epitopes 
Since mAbs 154, 165 and 168 are important candidates for 
site-specific phosphorylation studies, we then examined the 
binding role of individual residues within their epitopes, paying 
particular attention to the role of yTyr3’j5. Fig. 4 shows the 
binding results for a series of analogues of the original nona- 
peptide in which one residue at a time was substituted by 
alanine or other test amino acids. Almost any single residue 
could be replaced by Ala without any dramatic reduction in the 
binding ability of the peptide with two exceptions: yLys368 was 
critical for binding of mAbs 154 and 168, while 
the phosphorylatable yTyr365 was indispensable for mAb 165 
binding. 
3.3. Tyrosine phosphorylation of AChR inhibits mAb 165 
binding 
We then tested the effect of tyrosine phosphorylation of the 
AChR on the binding of mAbs which bind to yTyr365. Mem- 
brane-bound AChR was partially tyrosine phosphorylated by 
endogenous protein tyrosine kinases and [Y-~~P]ATP. Control 
samples, in which MnCl, was omitted, resulted in very weak 
labelling. The 32P-labelled membranes were then solubilized 
using Triton X-100 and their 32P-labelled AChR molecules im- 
munoprecipitated by anti-AChR mAbs. Since the fraction of 
the AChR phosphorylated in vitro was approximately 0.1-0.2, 
most labelled molecules would be expected to have only one 
32P-labelled subunit (j, y or s). Any mAb unable to bind to the 
phosphorylated y-subunit would thus still be able to precipitate 
AChR molecules labelled on their /? and/or 6 subunits. 
Although differences in mAb affinity for the AChR would 
be expected to result insignificant differences in the total 
amount of precipitated radioactivity, the distribution of the 
radioactivity precipitated between the three subunits 6/y/b 
should be constant for all mAbs whose binding is not affected 
by AChR tyrosine phosphorylation and should differ for those 
mAbs whose binding is affected by AChR tyrosine phosphoryl- 
ation. 
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Fig. 3. Summary of the epitope locations. The epitopes determined in 
the study are represented by horizontal bars corresponding to the 
shown Torpedo y-subunit segment. Shadowed parts of the bars denote 
that the corresponding residues enhanced, but were not essential for, 
mAb binding. 
The resulting autoradiograms, shown in Fig. 5, demonstrate 
that mAb 165 precipitated proportionally a much lower 
amount of labelled y-subunit than did the other mAbs and that 
mAbs 114 and 134, which bind to the tyrosine phosphorylation 
sites of the p and 6 subunits [9,12], precipitated AChRs with 
proportionally a much lower amount of the corresponding 
labelled subunits (Fig. 5). 
4. Discussion 
In the present study, we have precisely localised the sequen- 
tial epitopes of five mAbs directed against the AChR y-subunit 
and provided a molecular basis for previously noted character- 
istics of these mAbs (see below). The epitopes containing the 
tyrosine phosphorylation site of the y-subunit were character- 
ized in depth in order to determine the basis of binding and to 
provide highly specific tools for subsequent phosphorylation 
studies. The observations that one of the mAbs directed against 
this site blocks AChR channel function and that another differ- 
entiates between phosphorylated and non-phosphorylated 
y-subunit enhances the potential of these mAbs. 
Nelson et al. [13] found that mAbs 154, 165 and 168 bind to 
the 20-peptide ~358377 (IMIKAEEYILKKPRSELMFE) 
which contains the presently identified epitopes. They also 
found that mAbs 154 and 168, but not mAb 165, bind to the 
adult, but not the embryonic, bovine AChR. The homologous 
20-peptides of adult and embryonic AChR are LLLR- 
AEELILKKPRSEY-FE and PITAGEEVALCLPRSELLFR, - 
respectively. Based on sequence homologies and mAb cross- 
reactivity, the authors suggested that mAbs 154 and 168 bind 
between ~364-373 (which contains the presently identified epi- 
topes ~364-372) but that mAb 165 binds between ~357-362 
(distinct from theactual epitope). Our results (Fig. 4) now ex- 
plain the different cross-reactivity pattern seen between mAb 
165 and mAbs 154 and 168 with adult bovine AChR. Although 
these mAbs have almost identical epitopes which differ from 
the bovine adult sequence only at position 365 (Y versus L), 
Tyr 365 is indispensable for mAb 165 binding to the peptide, but 
is not required in the case of mAbs 154 and 168; in fact, it can 
be substituted by any of the tested amino acids (including Leu, 
which occurs inthe adult bovine AChR) without any effect on 
their binding (see Fig. 4). In contrast, the epitopes of the three 
mAbs differ dramatically in the corresponding bovine embry- 
onic y-subunit, thus explaining the lack of binding to embry- 
onic bovine AChR. 
In earlier competition experiments, using mAbs which bind 
to the intact Torpedo AChR [21], we found, in agreement with 
the present mapping studies, that mAbs 154, 165 and 168 com- 
pletely competed with one another for binding to the AChR. 
However, although they did not compete with many other 
mAbs directed against other subunits, two (mAbs 154 and 168) 
competed well with mAbs 128 and 129 which bind to the appar- 
ently extracellular C-terminal end of the a-subunit [12]. mAbs 
128 and 129 also compete with a mAb directed against the 
cytoplasmic region 6363-374 [21]. It is probable that the C- 
terminal end of the &subunit is able to move freely and that, 
in the Triton-solubilized AChR, a conformational rearrange- 
ment occurs, allowing this segment to approach the cytoplas- 
mic regions. Nevertheless, we cannot exclude an allosteric inter- 
action between extracellular and cytoplasmic sites. 
mAb 7 binds to both the y and 6 subunits of the Torpedo 
AChR [17]. We recently identified its epitope on the &subunit 
as segment 6389-396 (RHGLVPRV) [12]. Its presently mapped 
epitope ~382~387 (RHGLKR) contains the conserved segment 
RHGL and this might account for part of the cross-reactive 
character of this mAb. Infact, mAb 7 binds detectably to the 
RHGL peptide (35% of its binding to theRHGLKR peptide, 
Fig. 2). This epitope falls within the 20-peptide ~3733392 of 
Nelsonet al. [13], although it differs significantly from their 
deduced putative epitope (mainly ~3733380, possibly extending 
to 384). mAb 7 also binds to both adult and embryonic bovine 
AChR. Although the RHGL residues are not preserved in the 
bovine y and E subunits, they are preserved in the bovine 
&subunit which probably accounts for the observed cross-reac- 
tivity. 
Binding of mAb 145 is Torpedo-specific; this is explained by 
the fact that its identified epitope (~392-397, TSDIDI) is com- 
pletely different in the corresponding segments of the y and 
E-subunits of mammalian species. 
The epitopes of mAbs 154, 165 and 168 contain the y-subunit 
tyrosine phosphorylation site. The binding of mAbs 165 is 
much weaker when the y-subunit of the AChR is 
phosphorylated. In addition, even conservative substitutions of 
yTyr3’j5 dramatically inhibited mAb 165 binding to the peptide. 
mAb 168, together with the anti-p-subunit mAb 148 (which also 
E Y I LKKPRS 
Analogues of ~364-372 
Fig. 4. Binding of mAbs to single residue analogues of the peptide 
~364-373. Experimental conditions as in Fig. 1. Black bars show bind- 
ing to the original peptide. Original substituted residues are shown 
below the peptides. Each residue was substituted by alanine, except in 
the case of yTy? which was substituted by three additional amino 
acids. Substitutions are underlined. 
198 
y6r 
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Fig. 5. mAb binding to 32P tyrosine phosphorylated Torpedo AChR. 
AChR-rich Torpedo membranes were partially phosphorylated by en- 
dogenous tyrosine kinase, using [Y-~*P]ATP. The subsequent Triton 
X-IOO-solubilized extracts were incubated with the Sepharose-immobi- 
lized test mAbs. The pellets were analysed by SDS-PAGE and autora- 
diography. mAbs whose binding was inhibited by phosphorylation of 
the corresponding epitopes would selectively precipitate AChRs in 
which the corresponding subunit was unlabelled; thus the relative inten- 
sities of the precipitated subunits corresponding to such mAbs would 
be different from the control mAbs. Note that mAb 165 precipitated 
a proportionally much lower amount of labelled y-subunit compared 
to the other mAbs. mAbs 148 and 134, which bind to non- 
phosphorylated flyr372 [9] and fly?” [12], bound weakly to the 
phosphorylated /3- and B-subunits, respectively. 
binds at thep-subunit tyrosine phosphorylation site [9]), are the 
only two mAbs, out of 60 mAbs previously tested, that effec- 
tively inhibit AChR function [lo, 1 l] (two more mAbs are weak 
inhibitors). Therefore, the previously observed association be- 
tween overall tyrosine phosphorylation of the AChR and its ion 
channel function [6] has now been dissected at the level of 
individual tyrosine phosphorylation sites: i.e. each of at least 
two tyrosine phosphorylation sites on the B- and y-subunits is 
itself capable of strongly influencing the channel. 
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